NDAORALTABLETPriority Review
Approved
Jul 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTOS (pioglitazone) is an oral small-molecule thiazolidinedione approved in 1999 for type 2 diabetes management. It works by activating peroxisome proliferator-activated receptors (PPARγ) to improve insulin sensitivity and reduce hepatic glucose production. The drug is indicated for monotherapy or combination therapy in patients with inadequate glycemic control.
$0.948MPart D
LOE ApproachingDeclining
Declining Part D spending and approaching loss of exclusivity signal a mature brand with shrinking team size; career growth will depend on defensive strategies and potential combination therapy repositioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
Started Mar 2026
32 enrolled
Healthy Participants
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Started Jan 2025
120 enrolled
Type 2 DiabetesFatty Liver
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
Started Sep 2024
67 enrolled
Radiation DiseaseCognitive ImpairmentDrug Effect
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Started Aug 2024
606 enrolled
T2DM
Lactobreath: A Study to Diagnose Lactose Intolerance Using Breath Markers
Started Jun 2024
112 enrolled
Lactose Intolerance
Worked on ACTOS at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.